Filing Flows › Biolargo (BLGO) › Q1 2026
Biolargo (BLGO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Biolargo (BLGO) reported revenue of $1.1M for the first quarter 2026 (Q1 2026), -66% from a year earlier and +81% from the quarter before. Operating margin was -287.4%, net loss $3.4M (305.4% of revenue).
Biolargo, Q1 2026: revenue $1.1M (-66% year over year), operating margin -287.4%, net loss $3.4M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +81% | -66% |
| Operating profit | −$3.2M | — | — |
| Net earnings | −$3.4M | — | — |
| Operating cash flow | −$2.9M | — | — |
What changed
Revenue was $1.1M in Q1 2026, down 66% year over year and up 81% from the previous quarter. Product was the largest line at 52% of revenue. Product lost $2.2M year over year (down 79%), 103% of the total change.
Gross margin was 41.1%, down 4.4 points from Q1 2025. Operating costs exceeded revenue by $3.2M, an operating margin of -287.4%. Operating expenses grew 9% against a revenue fall of 66%. The fastest-growing cost line was Research & development (+15%). The quarter ended with a net loss of $3.4M, narrower than the previous quarter's $4.1M loss. Minority interests bore $1.1M of it: to shareholders the quarter was a loss of $2.3M.
Operating cash flow was −$2.9M. Non-cash charges added back $34K of depreciation and $699K of share-based compensation. Working capital and other items used $245K.
Questions
What was Biolargo's revenue in the first quarter 2026?
Biolargo (BLGO) reported revenue of $1.1M for the first quarter 2026 (Q1 2026), -66% from a year earlier and +81% from the quarter before.
Was Biolargo profitable in the first quarter 2026?
Operating loss was $3.2M (-287.4% of revenue) and net loss $3.4M.
Source: Biolargo 10-Q on SEC EDGAR.